Daim Safi Ur Rehman, Alsermani Aya, Althomali Renad Khalid, Ashraf Muhammad Fawad, AlSermani Maamoun
Mayo hospital, Anarkali, Lahore 54000, Punjab, Pakistan.
Department of Medicine, Dar Al Uloom University, Riyadh, Saudi Arabia.
Radiol Case Rep. 2024 Jul 13;19(9):4087-4090. doi: 10.1016/j.radcr.2024.06.022. eCollection 2024 Sep.
COVID-19 vaccines, a cornerstone of the fight against the disease have generally proven to be safe with most commonly reported side effects being mild and self-limiting. Uncommon severe adverse effects like thromboembolism have been reported during postmarketing surveillance. Viral-based vector vaccines have been most commonly implicated in these reports. Our report however portrays a case of a 26-year-old female who developed extensive pulmonary embolism following administration of the Pfizer- BNT162b2 mRNA COVID-19 vaccine. The patient did not have any risk factors for thromboembolism. She was admitted, put on enoxaparin, and given Altaplase thrombolytic therapy. Her condition improved and she was discharged on Apixaban. The Thrombophilia screen performed on the 6-month follow-up was negative and following the resolution of thrombosis, Apixaban was stopped. Our case highlights the importance of continued surveillance of uncommon adverse effects and the need for prompt diagnosis and management of such side effects.
新冠病毒疾病疫苗是抗击该疾病的基石，总体而言已证明是安全的，最常报告的副作用轻微且具有自限性。上市后监测期间报告了如血栓栓塞等罕见的严重不良反应。基于病毒载体的疫苗在这些报告中最常被牵连。然而，我们的报告描述了一名26岁女性在接种辉瑞-BNT162b2 mRNA新冠病毒疾病疫苗后发生广泛肺栓塞的病例。该患者没有任何血栓栓塞的危险因素。她入院后，接受了依诺肝素治疗，并给予阿替普酶溶栓治疗。她的病情好转，出院时服用阿哌沙班。6个月随访时进行的血栓形成倾向筛查为阴性，血栓溶解后，停用了阿哌沙班。我们的病例强调了持续监测罕见不良反应的重要性以及对此类副作用进行及时诊断和管理的必要性。
